Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics

Broad range RNA integrity and quality analysis kit for SCIEX capillary electrophoresis instruments launches at TIDES 2022

At TIDES 2022, SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches the RNA 9000 Purity & Integrity kit, for the BioPhase 8800 system and PA 800 Plus system.

As genomic medicine takes center stage and the demand for RNA-based therapeutics and vaccines grows, the integrity and quality of RNA species is increasingly important. Scientists have been faced with complex methods that have low resolution and poor transferability, as they work to accelerate therapeutic drug development and meet critical timelines. For intact mRNA analysis, scientists need validated, production-ready methods and instrument platforms that allow them to confidently distinguish desired therapeutic products from unwanted impurities.

This RNA 9000 Purity and Integrity kit is a purpose-built, high resolution analysis method for mRNA therapeutics. It was specifically designed to provide significantly higher resolution for a wide variety of therapeutically-relevant mRNA classes, from 50-9,000 bases.

“For scientists, this kit has the power and capability to transform the analysis of mRNA therapeutics and vaccines. Not only can it be used for final product quality control to assess quality and length post nanoparticle or viral vector encapsulation, but it can also be used during early-stage development immediately following IVT (in-vitro transcribe) to ensure the integrity and size of the mRNA payload is what the researchers are targeting. This kit is truly a unique solution with its analytical resolution,” said Jérémie Parot PhD, Research Scientist at SINTEF.

“The ability to help biopharmaceutical developers accelerate the development of RNA-based medicines and bridge the developability gap can bring more life-changing medicines to market,” said Susan Darling, Senior Director of CE and Biopharma at SCIEX. “Compatibility with both the BioPhase 8800 system and the PA 800 Plus system means scientists have the ability to run the assay in a 21cfr part 11b compliant way, across instruments, across sites, across the globe.”

With this kit, scientists could expect to:

  • Minimize time to market with exceptional reproducibility, experiment to experiment
  • Estimate a target therapeutic size
  • Experiment with minimal sample material and have the ability to detect low level impurities present in samples

To learn more about RNA 9000 Purity and Integrity kit, see here.

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com.

Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2022 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-14725-A.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.